Introducing baselines for therapeutic use of regulatory T cells and cytokines in autoimmunity

Trends in Immunology

Volumn 24, Issue 10, 2003, Pages 540-545

  Von Herrath, Matthias ^a   Homann, Dirk ^b  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; RECOMBINANT GAMMA INTERFERON; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL ACTIVITY; CELL FUNCTION; CELL INTERACTION; CELLULAR IMMUNITY; CONCEPT FORMATION; DISEASE MODEL; EXPERIMENTAL MODEL; HEMOSTASIS; HOMEOSTASIS; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOREGULATION; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TARGET CELL; TH1 CELL; TUMOR IMMUNITY;

EID: 0141670817     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2003.08.004     Document Type: Article

References (54)

1. Ehrlich P., Morgenroth J. Zytotoxine als Antikörper. Berl Klin Wochenschr. 38:1901;251-260.
2. Arstila T.P., et al. A direct estimate of the human αβ T cell receptor diversity. Science. 286:1999;958-961.
3. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol. Today. 19:1998;395-404.
4. Walker L.S., Abbas A.K. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat. Rev. Immunol. 2:2002;11-19.
5. Silverstein A. A history of immunology. 1989;Academic Press.
6. Gershon R.K., Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology. 18:1970;723-737.
7. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2:2002;389-400.
8. Shevach E.M. Regulatory T cells in autoimmmunity. Annu. Rev. Immunol. 18:2000;423-449.
9. Wood K.J., Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 3:2003;199-210.
10. Wilson S.B., Delovitch T.L. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat. Rev. Immunol. 3:2003;211-222.
11. von Herrath M.G., Harrison L.C. Antigen-induced regulatory T cells in autoimmunity. Nat. Rev. Immunol. 3:2003;223-232.
12. Hayday A., Tigelaar R. Immunoregulation in the tissues by γδ T cells. Nat. Rev. Immunol. 3:2003;233-242.
13. Bluestone J.A., Abbas A.K. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3:2003;253-257.
14. Bach J.F. Regulatory T cells under scrutiny. Nat. Rev. Immunol. 3:2003;189-198.
15. Calabrese E.J., Baldwin L.A. HORMESIS: the dose-response revolution. Annu. Rev. Pharmacol. Toxicol. 43:2003;175-197.
16. Hill N., Sarvetnick N. Cytokines: promoters and dampeners of autoimmunity. Curr. Opin. Immunol. 14:2002;791-797.
17. Sarvetnick N., et al. Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-γ Cell. 52:1988;773-782.
18. Hultgren B., et al. Genetic absence of γ-interferon delays but does not prevent diabetes in NOD mice. Diabetes. 45:1996;812-817.
19. von Herrath M.G., Oldstone M.B. Interferon-γ is essential for destruction of β cells and development of insulin-dependent diabetes mellitus. J. Exp. Med. 185:1997;531-539.
20. Sobel D.O., et al. γ interferon paradoxically inhibits the development of diabetes in the NOD mouse. J. Autoimmun. 19:2002;129-137.
21. Holz A., et al. Constitutive β cell expression of IL-12 does not perturb self-tolerance but intensifies established autoimmune diabetes. J. Clin. Invest. 108:2001;1749-1758.
22. Trembleau S., et al. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J. Exp. Med. 181:1995;817-821.
23. Trembleau S., et al. IL-12 administration accelerates autoimmune diabetes in both wild-type and IFN-γ-deficient nonobese diabetic mice, revealing pathogenic and protective effects of IL-12-induced IFN-γ J. Immunol. 170:2003;5491-5501.
24. Trembleau S., et al. Pancreas-infiltrating Th1 cells and diabetes develop in IL-12-deficient nonobese diabetic mice. J. Immunol. 163:1999;2960-2968.
25. Trembleau S., et al. Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes. Eur. J. Immunol. 27:1997;2330-2339.
26. Ymer S.I., et al. Polymorphisms in the IL-12β gene affect structure and expression of IL-12 in NOD and other autoimmune-prone mouse strains. Genes Immun. 3:2002;151-157.
27. Rossi D., Zlotnik A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18:2000;217-242.
28. Shull M.M., et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature. 359:1992;693-699.
29. Gorelik L., Flavell R.A. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 12:2000;171-181.
30. Lee M.S., et al. Transforming growth factor-β fails to inhibit allograft rejection or virus-induced autoimmune diabetes in transgenic mice. Transplantation. 61:1996;1112-1115.
31. King C., et al. TGF-β1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype. Immunity. 8:1998;601-613.
32. Piccirillo C.A., et al. TGF-β1 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice. J. Immunol. 161:1998;3950-3956.
33. Nakamura K., et al. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor β J. Exp. Med. 194:2001;629-644.
34. + T suppressor cell clones produce transforming growth factor β, but not interleukin 10, and are distinct from type 1 T regulatory cells. J. Exp. Med. 196:2002;1335-1346.
35. Piccirillo C.A., et al. CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor β1 production and responsiveness. J. Exp. Med. 196:2002;237-246.
36. Gorelik L., Flavell R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat. Med. 7:2001;1118-1122.
37. Wang B., et al. Interleukin-4 deficiency does not exacerbate disease in NOD mice. Diabetes. 47:1998;1207-1211.
38. + T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. Immunity. 11:1999;463-472.
39. Mueller R., et al. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 184:1996;1093-1099.
40. Muller W., et al. Interleukin-4-deficient mice. Res. Immunol. 144:1993;637-638.
41. Kuhn R., et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 75:1993;263-274.
42. Roncarolo M.G., et al. Type 1 T regulatory cells. Immunol. Rev. 182:2001;68-79.
43. Wogensen L., et al. Production of interleukin 10 by islet cells accelerates immune-mediated destruction of β cells in nonobese diabetic mice. J. Exp. Med. 179:1994;1379-1384.
44. Kawamoto S., et al. Suppression of T(h)1 cell activation and prevention of autoimmune diabetes in NOD mice by local expression of viral IL-10. Int. Immunol. 13:2001;685-694.
45. Christen U., et al. A dual role for TNF-α in type 1 diabetes: islet-specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis. J. Immunol. 166:2001;7023-7032.
46. Stockinger B., et al. T cell regulation: a special job or everyone's responsibility? Nat. Immunol. 2:2001;757-758.
47. Barthlott T., et al. T cell regulation as a side effect of homeostasis and competition. J. Exp. Med. 197:2003;451-460.
48. + splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J. Immunol. 169:2002;2461-2465.
49. Hall B.M., et al. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Mediation of specific suppression by T helper/inducer cells. J. Exp. Med. 162:1985;1683-1694.
50. Asseman C., et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190:1999;995-1004.
51. Sakaguchi S., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:1995;1151-1164.
52. + regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. J. Immunol. 168:2002;5979-5983.
53. + regulatory T cells control Leishmania major persistence and immunity. Nature. 420:2002;502-507.
54. Lee P.T., et al. Testing the NKT cell hypothesis of human IDDM pathogenesis. J. Clin. Invest. 110:2002;793-800.